Anti-CD19 CAR-T cells(University of Utah)(Anti-CD19 CAR-T cells(University of Utah)) - 药物靶点：CD19_在研适应症：急性淋巴细胞白血病，CD19 表达恶性肿瘤，弥漫性大B细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名

Anti-CD19 Chimeric Antigen Receptor T Cells

靶点

CD19

作用机制

CD19调节剂(B淋巴细胞抗原CD19调节剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

急性淋巴细胞白血病CD19 表达恶性肿瘤弥漫性大B细胞淋巴瘤

非在研适应症-

原研机构

University of Utah

在研机构

University of Utah

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Anti-CD19 CAR-T cells(University of Utah) 相关的临床试验

NCT06227026 / Recruiting临床1期IIT

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells.
This study will utilize a staggered enrollment design with a safety observation period.

开始日期2024-02-20

申办/合作机构

University of Utah

KCT0009199 / Recruiting临床2期IIT

Treatment of CD19 Chimeric Antigen Receptor T cells for Pediatric Patients with CD19-positive B-cell Acute Lymphoblastic Leukemia who are Indicated for Hematopoietic Stem Cell Transplantation

开始日期2024-01-19

申办/合作机构

Seoul National University Hospital

NCT04289220 / Unknown status临床1期IIT

A Phase I Clinical Trial of Anti-CD19 Chimeric Antigen Receptor in PiggyBac Transposon-Engineered T Cells for the Treatment of Patients With Relapsed/Refractory/High-risk B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

Our previous study demonstrated that anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells have strong tumor-killing activity in vitro and therapeutic effects in cell line-derived xenograft models, and no obvious side effects such as neurotoxicity and cytokine storm occurred. Therefore, we want to evaluate the safety and clinical effect of anti-CD19 CAR-T cells in clinical trials.

开始日期2020-03-15

申办/合作机构-

100 项与 Anti-CD19 CAR-T cells(University of Utah) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19 CAR-T cells(University of Utah) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19 CAR-T cells(University of Utah) 相关的专利（医药）

登录后查看更多信息

22

项与 Anti-CD19 CAR-T cells(University of Utah) 相关的文献（医药）

2024-06-01·Zhongguo shi yan xue ye xue za zhi

[Research Progress of CAR-T Cell Immunotherapy in B-Cell Non-Hodgkin's Lymphoma--Review].

Review

作者: Tian, Chen ; Wang, Mei-Yi

题目CAR-T细胞免疫疗法在B细胞非霍奇金淋巴瘤中的应用进展.摘要嵌合抗原受体T（CAR-T）细胞疗法是近年来迅速发展的免疫治疗新方法。相对于其他疗法，CAR-T疗法在高危及复发/难治性B细胞非霍奇金淋巴瘤（B-NHL）患者中具有显著优势。目前多种抗CD-19 CAR-T细胞已被FDA批准用于B-NHL的治疗，如阿基仑赛、司利弗明、利基迈仑赛、贝林妥欧单抗。除此之外，许多研究正在积极探索和开发不同靶点的CAR-T细胞，它们在B-NHL的治疗中表现出巨大的潜力。本文就CAR-T在常见B-NHL中的最新应用研究进展作一综述。 .

2024-05-15·Bioconjugate Chemistry

Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System

Article

作者: Chen, Kai-Ming ; Duan, Cai-Wen ; Huang, Xiu-Song ; Abudureheman, Tuersunayi ; Yang, Li-Ting ; Zhou, Hang ; Jing, Jun-Jie

Chimeric antigen receptor T-cell (CAR-T cell) therapy has become a promising treatment option for B-cell hematological tumors. However, few optional target antigens and disease relapse due to loss of target antigens limit the broad clinical applicability of CAR-T cells. Here, we conjugated an antibody (Ab) fusion protein, consisting of an Ab domain and a SpyCatcher domain, with the FITC-SpyTag (FITC-ST) peptide to form a bispecific safety switch module using a site-specific conjugation system. We applied the safety switch module to target CD19, PDL1, or Her2-expressing tumor cells by constructing FMC63 (anti-CD19), antiPDL1, or ZHER (anti-Her2)-FITC-ST, respectively. Those switch modules significantly improved the cytotoxic effects of anti-FITC CAR-T cells on tumor cells. Additionally, we obtained the purified CD8⁺ T cells by optimizing a shorter version of the CD8-binding aptamer to generate anti-FITC CD8-CAR-T cells, which combined with the CD4-FITC-ST switch module (anti-CD4) to eliminate the CD4-positive tumor cells in vitro and in vivo. Overall, we established a novel safety switch module by site-specific conjugation to enhance the antitumor function of universal CAR-T cells, thereby expanding the application scope of CAR-T therapy and improving its safety and efficacy.

2023-08-01·Current medical science

Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.

Article

作者: Wang, Xiao-Qi ; Kong, Pei-Yan ; Zhang, Cheng ; Tan, Xu ; Zhao, Xian-Lan ; Gao, Lei ; Wen, Qin ; Yao, Han ; Gao, Li ; Shen, Yan ; Lou, Shi-Feng ; Zhang, Xi ; Ma, Ying-Ying ; Chen, Guo

OBJECTIVEThis study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for treating relapsed CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).METHODSClinical data of 43 patients with B-ALL who relapsed after allo-HSCT were retrospectively analyzed. Twenty-two patients were treated with CAR-T cells (CAR-T group), and 21 with chemotherapy plus DLI (chemo-DLI group). The complete remission (CR) and minimal residual disease (MRD)-negative CR rates, leukemia-free survival (LFS) rate, overall survival (OS) rate, and incidence of acute graft-versus-host disease (aGVHD), cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were compared between the two groups.RESULTSThe CR and MRD-negative CR rates in the CAR-T group (77.3% and 61.5%) were significantly higher than those in the chemo-DLI group (38.1% and 23.8%) (P=0.008 and P=0.003). The 1- and 2-year LFS rates in the CAR-T group were superior to those in the chemo-DLI group: 54.5% and 50.0% vs. 9.5% and 4.8% (P=0.0001 and P=0.00004). The 1- and 2-year OS rates in the CAR-T versus chemo-DLI group were 59.1% and 54.5% vs. 19% and 9.5% (P=0.011 and P=0.003). Six patients (28.6%) with grade 2-4 aGVHD were identified in the chemo-DLI group. Two patients (9.1%) in the CAR-T group developed grade 1-2 aGVHD. Nineteen patients (86.4%) developed CRS in the CAR-T group, comprising grade 1-2 CRS in 13 patients (59.1%) and grade 3 CRS in 6 patients (27.3%). Two patients (9.1%) developed grade 1-2 ICANS.CONCLUSIONDonor-derived anti-CD19 CAR-T-cell therapy may be better, safer, and more effective than chemo-DLI for B-ALL patients who relapse after allo-HSCT.

100 项与 Anti-CD19 CAR-T cells(University of Utah) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性淋巴细胞白血病	临床1期	美国	University of Utah	2024-02-20
CD19 表达恶性肿瘤	临床1期	美国	University of Utah	2024-02-20
弥漫性大B细胞淋巴瘤	临床1期	美国	University of Utah	2024-02-20